Professor Graham Mann

MBBS, PhD, FRACP
Professor of Medicine, Westmead Clinical School
Co-Director. Centre for Cancer Research, Westmead Millennium Institute for Medical Research

Telephone +61 2 9845 9056
Fax +61 2 9845 9102

Website Related website

Map

Biographical details

Professor Graham Mann is an internationally renowned cancer geneticist and a leading Australian translational research scientist, specialising in the study of melanoma. As Research Director of the Melanoma Institute Australia (MIA) Professor Mann helps lead a multidisciplinary melanoma research program across the University of Sydney, Macquarie University and at the QIMR Berghofer Medical Research Institute, funded by a NHMRC Program Grant. “My colleagues and I are working toward a clearly defined vision of curing melanoma”, says Professor Mann. His research program covers three themes: (a) understanding why melanoma develops, including its genetic and environmental risk factors; (b) explaining what makes some melanomas worse than others, and how the approach to any patient presenting with melanoma should be guided by molecular markers of prognosis; (c) developing new treatments to treat and cure the disease. His team’s work has led to the discovery of novel genetic risk factors in the Australian population, novel biomarkers of prognosis, and changes to government policy. The team’s research on the role of solarium exposure in melanoma in young adults led to government bans on commercial solaria around Australia. His group’s work is contributing to the NIH Cancer Genome Atlas and the International Cancer Genome Consortium, aiming to build a comprehensive genomic map of mutations in melanoma. Professor Mann is a founding member and principal investigator of the international melanoma genetics consortium GenoMEL. He is Chair of the University of Sydney Cancer Research Network, and a member of the NHMRC Health Care Committee and NSW Cancer Research Advisory Committee.

Research interests

Professor Mann’s research investigates all aspects of melanoma control, from population-based studies of genetic and environmental susceptibility to melanoma, and psychosocial aspects of melanoma risk, to molecular markers of diagnosis, prognosis and response to treatment.

Professor Mann is lead investigator of the only population-based study of early-onset melanoma, the Australian Melanoma Family Study (AMFS), which recruited 4,000 people in Sydney, Melbourne and Brisbane and remains a major resource for understanding the genetic epidemiology of melanoma. His group is also a primary contributor to GenoMEL and via both projects has identified many new common melanoma-susceptibility gene variations in the population, as well as novel mutations associated with high melanoma risk. Research defining the prevalence and distribution of these mutations in Australians has helped focus mutation testing and guide genetic counseling regarding melanoma in this country.

Studies of the psychosocial impact of melanoma susceptibility were among the first of their kind in the field, and have also informed appropriate clinical cancer genetics services for melanoma, and guided further translational research. His team’s work has demonstrated a 40% increased risk of melanoma before age 40 years in sunbed users, and showed that 75% of melanomas occurring before the age of 30 in solarium users could be attributed to solarium use. This has led to state government bans on commercial solaria.

Ongoing work in the melanoma research program is heavily focused on bringing a new molecular understanding to the diagnosis and treatment of melanoma, and has already identified new markers of clinical outcome. The group is also at the forefront of developing new targeted and immune therapies for melanoma. The Australian Melanoma Genome Project and NIH Cancer Genome Atlas projects are comprehensively mapping all the genetic and genomic abnormalities of melanoma. These studies are delivering the next generation of personalised diagnostics and new therapeutic targets for this cancer.

Selected grants

2015

  • Covaris Evolution Adaptive Focused Acoustic Ultrasonicator for enhancement of cancer research within the Sydney West Hub; Graham J, Clarke C, Mann G, deFazio A, George J, Liddle C, Booth D, Sintchenko V; Cancer Institute New South Wales/Equipment Grant.

2014

  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • CyTOF Mass Cytometry Platform; Fazekas de St Groth B, Weninger W, Richardson D, Halliday G, Gunning P, Hart D, Mann G, Goldys E, Jin D; Cancer Institute New South Wales/Equipment Grant.
  • Vertically integrated statistical modelling in multi-layered omics studies; Yang J, Mueller S, Mann G; Australian Research Council (ARC)/Discovery Projects (DP).
  • Genetic Epidemiology of Melanoma; Cust A, Mann G, Jenkins M, Hopper J; National Institutes of Health (USA)/Research Support.
  • Cyber-racism and community resilience; Hayward N, Hersey P, Kefford R, Kefford R, Thompson J, Hersey P, Mann G, Scolyer R; National Health and Medical Research Council (NHMRC)/Program Grants.
  • Risk stratification and clinical management of non-melanoma skin cancer in primary care and specialist dermatology settings; Mann G; Cancer Institute New South Wales/Translational Research Initiating Grant.
  • IncuCyte ZOOM; Rizos H, deFazio A, Mann G, Henderson B; DVC Research/Equipment Grant.

2012

  • Continuing Infrastructure Support for a flow cytometry specialist to manage and operate the expanded Westmead Reseach Hub Flow Cytometry Centre.; Mann G; Cancer Institute New South Wales/Research Infrastructure Grant.

2011

  • Melanoma Institute Australia Translational Research Program; Mann G, Thompson J, Kefford R, Menzies S, Scolyer R, Christopherson R, Rizos H, Spillane A, Zhang X, Hersey P; Cancer Institute New South Wales/Translational Program Grant.

2009

  • High-Throughput virtual microscopy and data warehouse system; Mann G, Schifter M, Balleine R, George J, Henderson B, Clarke C, Catchpoole D, deFazio A; Cancer Institute New South Wales/Equipment Grant.

2006

  • Sydney Melanoma Unit Translational Research Program; Mann G, Thompson J, Kefford R, Scolyer R, Menzies S, Hersey P, Christopherson R; Cancer Institute New South Wales/Translational Research Program Grant.
  • Genetic and environmental determinants of melanoma: translation into behavioural change; Mann G, Bishop J; EU 6th Framework - Network of Excellence/Sixth Framework Programme Priority 1.
  • Molecular genetics of melanoma predisposition; Mann G, Kefford R, Rizos H, Aitken J, Aitken J; Cancer Council New South Wales/Research Project Grants.
  • Molecular determinants of melanoma risk, progression and response to treatment; Kefford R, Thompson J, Hersey P, Mann G, Scolyer R; National Health and Medical Research Council (NHMRC)/Program Grants.

2005

  • Molcular genetics of melanoma predisposition; Mann G; University of Sydney/Bridging Support.
  • Psychosocial consequences of melanoma susceptibility; Kasparian N, Simpson J, Meiser B, Mann G, Butow P; University of New South Wales/Gold Star Award.
  • X-ray irradiator for cellular and molecular studies of the role of ionising radiation in carcinogenesis and DNA repair processes; Mann G; Cancer Institute New South Wales/Equipment Grant.

2004

  • Genetics of melanoma susceptibility and tumour suppression; Mann G, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Mapping & identification of novel breast cancer susceptibility genes; Mann G, Newman B, Venter D; National Breast Cancer Foundation/Research Grant.
  • Zebrafish model of melanoma susceptibility; Mann G; DVC Research/Research and Development Scheme: Research and Development (R&D).

2003

  • Novel effects of the p16INK4A melanoma susceptibility/tumour suppressor gene; Mann G; DVC Research/Research and Development Scheme: Research and Development (R&D).
  • Australian melanoma family study; Aitken J, Hopper J, Giles G, Armstrong B, Kefford R, Mann G; Queensland Cancer Fund /Research Grant.
  • Australian Melanoma Family Study; Mann G, Hopper J, Aitken J, Kefford R, Armstrong B, Giles G; Anti-Cancer Council of Victoria/Research Grant.
  • Sensory impairment: causes impacts and interventions; Mitchell P, Smith W, Cumming R, Leeder S, Wang J, Mann G, Michael M; National Health and Medical Research Council (NHMRC)/Capacity Building Grant.
  • FishWorks - collaborative infrastructure for zebrafish research; Mercer J, Lardelli M, Ward A, Perkins A, Mann G; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2002

  • Genetic Epidemiology of Melanoma; Elder D, Elder D, Mann G, Kefford R, Giles G, Hopper J; National Cancer Institute (USA)/Research Grant.
  • Molecular genetics of melanoma predisposition; Mann G, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Genetic susceptibility to non-melanoma skin cancer; Mann G; University of Sydney/Cancer Research Fund.
  • ProStar Helix DNA HPLC System; Mann G; University of Sydney/Equipment Grant.
  • Australian Melanoma Family Study; Mann G; Queensland Cancer Fund /Research Grant.
  • Australian Melanoma Study; Mann G, Hopper J, Aitken J, Kefford R, Giles G, Armstrong B; Anti-Cancer Council of Victoria/Research Grant.
  • Australian Melanoma Study; Hopper J, Aitken J, Kefford R, Giles G, Armstrong B, Mann G; Queensland Cancer Fund /Research Grant.
  • Biological safety cabinet for genetic studies; Mann G; Cecilia Kilkeary Foundation/Research Grant.
  • UV Spectroradiometer; Mann G, Halliday G, Mann G, Menzies S, Reeves V; Faculty of Medicine/Institutional Strengths.

2000

  • Australian Melanoma Study; Mann G, Hopper J, Aitken J, Kefford R, Giles G; Cancer Council New South Wales/Research Project Grants.
  • UV mutagenesis and CDKN2A (p16INK4A) function; Mann G, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Molecular genetics of melanoma predisposition; Mann G, Kefford R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Australian Melanoma family study; Mann G; Cancer Council New South Wales/Research Project Grants.
  • Transgenomic WAVE 2100 denaturing HPLC system for DNA variant analysis; Farrell G, Clarke C, Cunningham A, deFazio A, Kirk J, Leary J, Liddle C, Manolios N, Mitchell P, Stewart G, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Australian melanoma family study; Armstrong B, Mann G, Hopper J, Aitken J, Kefford R, Giles G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Mapping and identification of novel breast cancer susceptibility genes; Mann G, Newman B; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Molecular genetics of melanoma; Kefford R, Mann G; National Health and Medical Research Council (NHMRC)/Project Grants.

1999

  • Genetic abnormalities in naevi and early melanoma; Mann G; DVC Research/Cancer Research Fund.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Jayawardana, K., Schramm, S., Haydu, L., Thompson, J., Scolyer, R., Mann, G., Muller, S., Yang, J. (2015). Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. International Journal of Cancer, 136(4), 863-874. [More Information]
  • Dutton-Regester, K., Gartner, J., Emmanuel, R., Qutob, N., Davies, M., Gershenwald, J., Robinson, W., Robinson, S., Rosenberg, S., Scolyer, R., Mann, G., Thompson, J., et al (2014). A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 5(10), 2912-2917.
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • Song, F., Amos, C., Lee, J., Lian, C., Fang, S., Liu, H., MacGregor, S., Iles, M., Law, M., Lindeman, N., Cust, A., Kefford, R., Armstrong, B., Mann, G., et al (2014). Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis, 35(9), 2097-2101. [More Information]
  • Dieng, M., Watts, C., Kasparian, N., Morton, R., Mann, G., Cust, A. (2014). Improving subjective perception of personal cancer risk: systematic review and meta-analysis of educational interventions for people with cancer or at high risk of cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 23(6), 613-625. [More Information]
  • Lu, Y., Weronica, E., Whiteman, D., Vaughan, T., Spurdle, A., Easton, D., Pharoah, P., Thompson, D., Dunning, A., Hayward, N., Armstrong, B., Cust, A., Holland, E., Kefford, R., Mann, G., Schmid, H., et al (2014). Most common 'sporadic' cancers have a significant germline genetic component. Human Molecular Genetics, 23(22).
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Watts, K., Meiser, B., Wakefield, C., Barratt, A., Howard, K., Cheah, B., Mann, G., Lobb, E., Gaff, C., Patel, M. (2014). Online Prostate Cancer Screening Decision Aid for At-Risk Men: A Randomized Trial. Health Psychology, 33(9), 986-997. [More Information]
  • Harland, M., Cust, A., Badenas, C., Chang, Y., Holland, E., Aguilera, P., Aitken, J., Armstrong, B., Barrett, J., Carrera, C., Agha-Hamilton, C., Kefford, R., Kolm, I., Schmid, H., Mann, G., et al (2014). Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hereditary Cancer in Clinical Practice.
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]
  • Iles, M., Bishop, D., Taylor, J., Hayward, N., Brossard, M., Cust, A., Dunning, A., Lee, J., Moses, E., Akslen, L., Mann, G., et al (2014). The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 106(10). [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.
  • Iles, M., Law, M., Stacey, S., Han, J., Fang, S., Pfeiffer, R., Harland, M., MacGregor, S., Taylor, J., Aben, K., Cust, A., Mann, G., et al (2013). A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 45(4), 428-432. [More Information]
  • Liu, H., Wang, L., Liu, Z., Chen, W., Amos, C., Lee, J., Iles, M., Law, M., Barrett, J., Montgomery, G., Cust, A., Mann, G., et al (2013). Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. Carcinogenesis, 34(4), 885-892. [More Information]
  • Qian, J., Liu, H., Wei, S., Liu, Z., Li, Y., Wang, L., Chen, W., Amos, C., Lee, J., Iles, M., Cust, A., Mann, G., et al (2013). Association between putative functional variants in the PSMB9 gene and risk of melanoma - re-analysis of published melanoma genome-wide association studies. Pigment Cell & Melanoma Research, 26(3), 392-401. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Mar, V., Wong, S., Li, J., Scolyer, R., McLean, C., Papenfuss, A., Tothill, R., Kakavand, H., Mann, G., Thompson, J., et al (2013). BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 19(17), 4589-4598. [More Information]
  • Connolly, K., Dhillon, H., Mann, B., Chua, B., Segelov, E. (2013). Breast cancer: Screening, prevention, support and other aspects. Medicine Today, 14(8), 29-36.
  • Schramm, S., Li, S., Jayaswal, V., Fung, D., Campain, A., Pang, C., Scolyer, R., Yang, J., Mann, G., Wilkins, M. (2013). Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell & Melanoma Research, 26(5), 708-722. [More Information]
  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Kakavand, H., Scolyer, R., Thompson, J., Mann, G. (2013). Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. OncoImmunology, 2(9), e25564-1-e25564-3. [More Information]
  • Gyorki, D., Shaw, T., Nicholson, J., Baker, C., Pitcher, M., Skandarajah, A., Segelov, E., Mann, B. (2013). Improving the impact of didactic resident training with online spaced education. ANZ Journal of Surgery, 83(6), 477-480. [More Information]
  • Cust, A., Goumas, C., Vuong, K., Davies, J., Barrett, J., Holland, E., Schmid, H., Agha-Hamilton, C., Armstrong, B., Kefford, R., Mann, G., et al (2013). MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: An Australian case-control-family study. BMC Cancer, 13(1), 1-13. [More Information]
  • McLoone, J., Watts, K., Menzies, S., Barlow-Stewart, K., Mann, G., Kasparian, N. (2013). Melanoma survivors at high risk of developing new primary disease: a qualitative examination of the factors that contribute to patient satisfaction with clinical care. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(9), 1994-2000. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]
  • Schramm, S., Menzies, A., Mann, G. (2013). Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Research, 23(6), 423-425. [More Information]
  • Schramm, S., Jayaswal, V., Goel, A., Li, S., Yang, J., Mann, G., Wilkins, M. (2013). Molecular interaction networks for the analysis of human disease: utility, limitations, and considerations. Proteomics, 13(23-24), 3393-3405. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • McLoone, J., Menzies, S., Meiser, B., Mann, G., Kasparian, N. (2013). Psycho-educational interventions for melanoma survivors: a systematic review. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(7), 1444-1456. [More Information]
  • Jayaswal, V., Schramm, S., Mann, G., Wilkins, M., Yang, J. (2013). VAN: an R package for identifying biologically perturbed networks via differential variability analysis. BMC Research Notes, 6(1), 1-9. [More Information]
  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Cust, A., Goumas, C., Holland, E., Agha-Hamilton, C., Aitken, J., Armstrong, B., Giles, G., Kefford, R., Schmid, H., Hopper, J., Mann, G., et al (2012). MC1R genotypes and risk of melanoma before age 40 years: A population-based case-control-family study. International Journal of Cancer, 131(3), E269-2E81. [More Information]
  • Law, M., Montgomery, G., Brown, K., Martin, N., Mann, G., Hayward, N., MacGregor, S. (2012). Meta-Analysis Combining New and Existing Data Sets Confirms that the TERT-CLPTM1L Locus Influences Melanoma Risk. Journal of Investigative Dermatology, 132(2), 485-487. [More Information]
  • Schramm, S., Campain, A., Scolyer, R., Yang, J., Mann, G. (2012). Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. Journal of Investigative Dermatology, 132(2), 274-283. [More Information]
  • Scurr, L., McKenzie, H., Becker, T., Irvine, M., Lai, K., Mann, G., Scolyer, R., Kefford, R., Rizos, H. (2012). Selective Loss of Wild-Type p16(INK4a) Expression in Human Nevi. Journal of Investigative Dermatology, 131(11), 2329-2332. [More Information]
  • Howard, K., Salkeld, G., Mann, G., Patel, M., Cunich, M., Pignone, M. (2012). The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study. BMJ Open, 2(1), 1-6. [More Information]
  • Kasparian, N., Sansom-Daly, U., McDonald, R., Meiser, B., Butow, P., Mann, G. (2012). The nature and structure of psychological distress in people at high risk for melanoma: A factor analytic study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 21(8), 845-856. [More Information]
  • Yokoyama, S., Woods, S., Boyle, G., Aoude, L., MacGregor, S., Zismann, V., Gartside, M., Cust, A., Haq, R., Harland, M., Holland, E., Schmid, H., Kefford, R., Armstrong, B., Mann, G., et al (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 480(7375), 99-103. [More Information]
  • Wakefield, C., Watts, K., Meiser, B., Sansom-Daly, U., Barratt, A., Mann, G., Lobb, E., Gaff, C., Howard, K., Patel, M. (2011). Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. Patient Education and Counseling, 83(1), 64-72. [More Information]
  • Cust, A., Jenkins, M., Goumas, C., Armstrong, B., Schmid, H., Aitken, J., Giles, G., Kefford, R., Hopper, J., Mann, G. (2011). Early-life sun exposure and risk of melanoma before age 40 years. Cancer Causes and Control, 22(6), 885-897. [More Information]
  • MacGregor, S., Montgomery, G., Liu, J., Zhao, Z., Henders, A., Stark, M., Schmid, H., Holland, E., Duffy, D., Zhang, M., Cust, A., Kefford, R., Armstrong, B., Mann, G., et al (2011). Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 43(11), 1114-1119. [More Information]
  • Amos, C., Wang, L., Lee, J., Gershenwald, J., Chen, W., Fang, S., Kosoy, R., Zhang, M., Qureshi, A., Vattathil, S., Mann, G., Cust, A., et al (2011). Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human Molecular Genetics, 20(24), 5012-5023. [More Information]
  • Barrett, J., Iles, M., Harland, M., Taylor, J., Aitken, J., Andresen, P., Akslen, L., Armstrong, B., Avril, M., Azizi, E., Cust, A., Kefford, R., Mann, G., et al (2011). Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 43(11), 1108-1113. [More Information]
  • Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]
  • Schramm, S., Mann, G. (2011). Melanoma Prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Molecular Cancer Therapeutics, 10(8), 1520-1528. [More Information]
  • Cust, A., Harland, M., Makalic, E., Schmidt, D., Dowty, J., Aitken, J., Agha-Hamilton, C., Armstrong, B., Barrett, J., Chan, M., Holland, E., Kefford, R., Schmid, H., Mann, G., et al (2011). Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. Journal of Medical Genetics, 48(4), 266-272. [More Information]
  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011). Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology, 29(10), 1239-1246. [More Information]
  • Cust, A., Armstrong, B., Goumas, C., Jenkins, M., Schmid, H., Hopper, J., Kefford, R., Giles, G., Aitken, J., Mann, G. (2011). Sunbed Use During Adolescence and Early Adulthood is Associated with Increased Risk of Early-Onset Melanoma. International Journal of Cancer, 128(10), 2425-2435. [More Information]
  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]
  • Demenais, F., Mohamdi, H., Chaudru, V., Goldstein, A., Newton Bishop, J., Bishop, D., Kanetsky, P., Hayward, N., Gillanders, E., Elder, D., Holland, E., Mann, G., et al (2010). Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. Journal of the National Cancer Institute, 102(20), 1568-1583. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • McKenzie, H., Fung, C., Becker, T., Irvine, M., Mann, G., Kefford, R., Rizos, H. (2010). Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Human Mutation, 31(6), 692-701. [More Information]
  • Kasparian, N., Mcloone, J., Meiser, B., Butow, P., Simpson, J., Mann, G. (2010). Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. British Journal of Cancer, 103, 1502-1509. [More Information]
  • Howard, K., Barratt, A., Mann, G., Patel, M. (2009). A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Archives of Internal Medicine, 169(17), 1603-1610. [More Information]
  • Morey, A., Murali, R., McCarthy, S., Mann, G., Scolyer, R. (2009). Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology, 41(4), 383-387. [More Information]
  • Scaini, M., Rossi, E., Torres, P., Zullato, D., Callegaro, M., Casella, C., Quaggio, M., Agata, S., Malacrida, S., Chiarion-Sileni, V., Mann, G., et al (2009). Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 671(1), 26-32. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Simpson, J., Mann, G. (2009). Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genetics in Medicine, 11(4), 265-278. [More Information]
  • Bishop, D., Demenais, F., Iles, M., Harland, M., Taylor, J., Corda, E., Randerson-Moor, J., Aitken, J., Kefford, R., Mann, G. (2009). Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 41(8), 920-925. [More Information]
  • Gartside, M., Chen, H., Ibrahimi, O., Byron, S., Curtis, A., Wellens, C., Bengston, A., Yudt, L., Eliseenkova, A., Ma, J., Mann, G., et al (2009). Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Molecular Cancer Research, 7(1), 41-54. [More Information]
  • Cust, A., Schmid, H., Maskiell, J., Jetann, J., Ferguson, M., Holland, E., Agha-Hamilton, C., Jenkins, M., Kelly, J., Kefford, R., Armstrong, B., Mann, G., et al (2009). Population-based, Case-Control-Family Design to Investigate Genetic and Environmental Influences on Melanoma Risk: Australian Melanoma Family Study. American Journal of Epidemiology, 170(12), 1541-1554. [More Information]
  • Leachman, S., Carucci, J., Kohlmann, W., Banks, K., Asgari, M., Bergman, W., Bianchi-Scarra, G., Brentnall, T., Bressac-de Paillerets, B., Bruno, W., Kefford, R., Mann, G. (2009). Selection criteria for genetic assessment of patients with familial melanoma. Journal Of The American Academy Of Dermatology, 61(4), 677.e1-677.e14. [More Information]
  • Becker, T., Haferkamp, S., Dijkstra, M., Scurr, L., Frausto, M., Diefenbach, E., Scolyer, R., Reisman, D., Mann, G., Kefford, R., Rizos, H. (2009). The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 8(4), 4-1-4-12. [More Information]
  • Mann, G., Harland, M., Goldstein, A., Kukalizch, K., Taylor, C., Hogg, D., Puig, S., Badenase, C., Gruis, N., ter Huurnef, J., et al (2008). A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). European Journal of Cancer, 44(9), 1269-1274. [More Information]
  • Brown, K., MacGregor, S., Montgomery, G., Craig, D., Zhao, Z., Iyadurai, K., Henders, A., Homer, N., Campbell, M., Stark, M., Schmid, H., Holland, E., Kefford, R., Armstrong, B., Mann, G., et al (2008). Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 40(7), 838-840. [More Information]
  • Kasparian, N., Butow, P., Meiser, B., Mann, G. (2008). High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 17(3), 270-279. [More Information]
  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]
  • Wakefield, C., Meiser, B., Gaff, C., Barratt, A., Patel, M., Suthers, G., Lobb, E., Ramsay, J., Mann, G. (2008). Issues Faced by Unaffected Men With a Family History of Prostate Cancer: A Multidisciplinary Overview. The Journal of Urology, 180(1), 38-46. [More Information]
  • Gallagher, S., Thompson, J., Indsto, J., Scurr, L., Lett, M., Gao, B., Dunleavey, R., Mann, G., Kefford, R., Rizos, H. (2008). p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. NeoPlasia: an international journal of oncology research, 10(11), 1231-1239. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Simpson, J., Mann, G. (2008). Predictors of psychological distress among individuals with a strong family history of malignant melanoma. Clinical Genetics, 73(2), 121-131. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Job, R., Mann, G. (2007). Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 69-78.
  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Esquivel, J., Sticca, R., Sugarbaker, P., Levine, E., Yan, T., Alexander, R., Baratti, D., Bartlett, D., Barone, R., Barrios, P., et al (2007). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Annals of Surgical Oncology, 14(1), 128-133. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology & Therapeutics, 82(1), 33-40. [More Information]
  • Indsto, J., Kumar, S., Wang, L., Crotty, K., Arbuckle, S., Mann, G. (2007). Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. Journal Of Cutaneous Pathology, 34(6), 448-455. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]
  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Soames Job, R., Mann, G. (2006). Anticipated uptake of genetic testing for familial melanoma in an Australian sample: an exploratory study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 69-78. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Job, R., Mann, G. (2006). Better the devil you know. High risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. Journal of Genetic Counseling, 15(6), 433-447. [More Information]
  • Goldstein, A., Chan, M., Harland, M., Hayward, N., Demenais, F., Bishop, D., Azizi, E., Bergman, W., Bianchi-Scarra, G., Bruno, W., Holland, E., Kefford, R., Mann, G., et al (2006). Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. Journal of Medical Genetics, 44(2), 99-106. [More Information]
  • Goldstein, A., Chan, M., Harland, M., Gillanders, E., Hayward, N., Avril, M., Azizi, E., Bianchi-Scarra, G., Bishop, D., Bressac-de Paillerets, B., Holland, E., Kefford, R., Mann, G., et al (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Research, 66(20), 9818-9828. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]
  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology & Therapeutics, 77(1), 33-42. [More Information]
  • Becker, T., Rizos, H., Dela Pena, A., Leclercq, I., Woodruff, S., Kefford, R., Mann, G. (2005). Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochemical and Biophysical Research Communications, 332(3), 873-879. [More Information]
  • Harland, M., Taylor, C., Bass, S., Churchman, M., Randerson-Moor, J., Holland, E., Mann, G., Bishop, D., Newton Bishop, J. (2005). Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes and Cancer, 43(2), 128-136. [More Information]
  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]
  • Becker, T., Ayub, A., Kefford, R., Mann, G., Rizos, H. (2005). The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. International Journal of Cancer, 117(4), 569-573. [More Information]
  • Walker, G., Indsto, J., Sood, R., Faruque, M., Hu, P., Pollock, P., Duray, P., Holland, E., Brown, K., Kefford, R., Mann, G., et al (2004). Deletion Mapping Suggests That The 1P22 Melanoma Susceptibility Gene Is A Tumor Suppressor Localized To A 9-Mb Interval. Genes Chromosomes and Cancer, 41(1), 56-64. [More Information]
  • Clancy, J., Henderson, M., Russell, A., Anderson, D., Bova, R., Campbell, I., Choong, D., Macdonald, G., Mann, G., Nolan, T., Davies, M., et al (2003). EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene, 22(32), 5070-5081. [More Information]
  • Camp, E., Badhwar, P., Mann, G., Lardelli, M. (2003). Expression analysis of a tyrosinase promoter sequence in zebrafish. Pigment Cell Research, 16(2), 117-126.
  • Indsto, J., Nassif, N., Kefford, R., Mann, G. (2003). Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma. Clinical Cancer Research, 9(17), 6476-6482.
  • Kefford, R., Mann, G. (2003). Is there a role for genetic testing in patients with melanoma? Current Opinion in Oncology, 15(2), 157-161.
  • Gillanders, E., Juo, S., Holland, E., Jones, M., Nancarrow, D., Freas-Lutz, D., Sood, R., Park, N., Faruque, M., Markey, C., Kefford, R., Mann, G., et al (2003). Localization of a novel melanoma susceptibility locus to 1p22. American Journal of Human Genetics, 73(2), 301-313. [More Information]
  • Hornbuckle, J., Culjak, G., Jarvis, E., Gebski, V., Coates, A., Mann, G., Kefford, R. (2003). Patterns of metastases in familial and non-familial melanoma. Melanoma Research, 13(1), 105-109.
  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.
  • Fung, D., Holland, E., Becker, T., Hayward, N., Bressac de Paillerets, B., Melanoma Genetics Consortium, M., Mann, G. (2002). EMelanoBase: An Online Locus-Specific Variant Database for Familial Melanoma. Human Mutation, 21(1), 2-7.
  • Thompson, D., Szabo, C., Mangion, J., Oldenburg, R., Odefrey, F., Seal, S., Barfoot, R., Kroeze-Jansema, K., Teare, D., Rahman, N., Mann, G., et al (2002). Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 99(2), 827-831.
  • Bishop, D., Demenais, F., Goldstein, A., Bergman, W., Bishop, J., Bressac de Paillerets, B., Chompret, A., Ghiorzo, P., Gruis, N., Hansson, J., Holland, E., Mann, G., et al (2002). Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma. Journal of the National Cancer Institute, 94(12), 894-903.
  • Indsto, J., Cachia, A., Kefford, R., Mann, G. (2001). Clonality analysis, deletions and microsatellite instability in common acquired melanocytic nevi compared with malignant melanoma. Clinical Cancer Research, 7(12), 4054-4059.
  • Becker, T., Rizos, H., Kefford, R., Mann, G. (2001). Functional Impairment of Melanoma-associated p16 INK4a mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding1. Clinical Cancer Research, 7, 3282-3288.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R., Holland, E. (2001). Mutations in the INK4a/ARF Melanoma Susceptibility locus functionally impair p14ARF. Journal of Biological Chemistry, 276(44), 41424-41434.
  • Shannon, J., Kefford, R., Mann, G. (2001). Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds. Melanoma Research, 11(1), 1-9.
  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.
  • Indsto, J., Cachia, A., Kefford, R., Mann, G. (2001). X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi. Clinical Cancer Research, 7(12), 4054-4059.
  • Cachia, A., Indsto, J., McLaren, K., Mann, G., Arends, M. (2000). CDKN2A mutation and deletion status in thin and thick primary melanoma. Clinical Cancer Research, 6(9), 3511-3515.
  • Harland, M., Holland, E., Ghiorzo, P., Mantelli, M., Bianchi-Scarra, G., Goldstein, A., Tucker, M., Ponder, B., Mann, G., Bishop, D., et al (2000). Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes and Cancer, 28(1), 45-57.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R. (2000). Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene, 19(26), 2978-2985.

Conferences

  • Barter, R., Schramm, S., Mann, G., Yang, J. (2014). Network-based biomarkers enhance classical approaches to prognostic gene expression signatures. International Conference on Bioinformatics 2014 (InCoB2014), Australia: BMC Public Health. [More Information]
  • Coates, E., Moloney, F., Guitera, P., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Melanoma detection in high risk patients: a case series. 20th Regional Conference of Dermatology 2012.
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Observation of a five year high risk clinic for primary melanoma. 3rd World Congress of Dermoscopy, Australia.

Patents

  • Thompson, J., Armstrong, B., Barbour, A., Barnetson, R., Beanland, H., Beer, T., Brookshank, M., Burmeister, B., Butow, P., Clark, K., Conway, R., Damian, D., Frommer, M., Kefford, R., Lee, S., Mason, R., Mann, G., McCarthy, W., Menzies, S., Olver, I., Quinn, M., Saw, R., Shaw, H., Stretch, J., Barraclough, B., Holt, P., Reeve, T., et al (2008).

2015

  • Jayawardana, K., Schramm, S., Haydu, L., Thompson, J., Scolyer, R., Mann, G., Muller, S., Yang, J. (2015). Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. International Journal of Cancer, 136(4), 863-874. [More Information]

2014

  • Dutton-Regester, K., Gartner, J., Emmanuel, R., Qutob, N., Davies, M., Gershenwald, J., Robinson, W., Robinson, S., Rosenberg, S., Scolyer, R., Mann, G., Thompson, J., et al (2014). A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 5(10), 2912-2917.
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • Song, F., Amos, C., Lee, J., Lian, C., Fang, S., Liu, H., MacGregor, S., Iles, M., Law, M., Lindeman, N., Cust, A., Kefford, R., Armstrong, B., Mann, G., et al (2014). Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis, 35(9), 2097-2101. [More Information]
  • Dieng, M., Watts, C., Kasparian, N., Morton, R., Mann, G., Cust, A. (2014). Improving subjective perception of personal cancer risk: systematic review and meta-analysis of educational interventions for people with cancer or at high risk of cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 23(6), 613-625. [More Information]
  • Lu, Y., Weronica, E., Whiteman, D., Vaughan, T., Spurdle, A., Easton, D., Pharoah, P., Thompson, D., Dunning, A., Hayward, N., Armstrong, B., Cust, A., Holland, E., Kefford, R., Mann, G., Schmid, H., et al (2014). Most common 'sporadic' cancers have a significant germline genetic component. Human Molecular Genetics, 23(22).
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Barter, R., Schramm, S., Mann, G., Yang, J. (2014). Network-based biomarkers enhance classical approaches to prognostic gene expression signatures. International Conference on Bioinformatics 2014 (InCoB2014), Australia: BMC Public Health. [More Information]
  • Watts, K., Meiser, B., Wakefield, C., Barratt, A., Howard, K., Cheah, B., Mann, G., Lobb, E., Gaff, C., Patel, M. (2014). Online Prostate Cancer Screening Decision Aid for At-Risk Men: A Randomized Trial. Health Psychology, 33(9), 986-997. [More Information]
  • Harland, M., Cust, A., Badenas, C., Chang, Y., Holland, E., Aguilera, P., Aitken, J., Armstrong, B., Barrett, J., Carrera, C., Agha-Hamilton, C., Kefford, R., Kolm, I., Schmid, H., Mann, G., et al (2014). Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hereditary Cancer in Clinical Practice.
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]
  • Iles, M., Bishop, D., Taylor, J., Hayward, N., Brossard, M., Cust, A., Dunning, A., Lee, J., Moses, E., Akslen, L., Mann, G., et al (2014). The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 106(10). [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.

2013

  • Iles, M., Law, M., Stacey, S., Han, J., Fang, S., Pfeiffer, R., Harland, M., MacGregor, S., Taylor, J., Aben, K., Cust, A., Mann, G., et al (2013). A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 45(4), 428-432. [More Information]
  • Liu, H., Wang, L., Liu, Z., Chen, W., Amos, C., Lee, J., Iles, M., Law, M., Barrett, J., Montgomery, G., Cust, A., Mann, G., et al (2013). Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. Carcinogenesis, 34(4), 885-892. [More Information]
  • Qian, J., Liu, H., Wei, S., Liu, Z., Li, Y., Wang, L., Chen, W., Amos, C., Lee, J., Iles, M., Cust, A., Mann, G., et al (2013). Association between putative functional variants in the PSMB9 gene and risk of melanoma - re-analysis of published melanoma genome-wide association studies. Pigment Cell & Melanoma Research, 26(3), 392-401. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Mar, V., Wong, S., Li, J., Scolyer, R., McLean, C., Papenfuss, A., Tothill, R., Kakavand, H., Mann, G., Thompson, J., et al (2013). BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 19(17), 4589-4598. [More Information]
  • Connolly, K., Dhillon, H., Mann, B., Chua, B., Segelov, E. (2013). Breast cancer: Screening, prevention, support and other aspects. Medicine Today, 14(8), 29-36.
  • Schramm, S., Li, S., Jayaswal, V., Fung, D., Campain, A., Pang, C., Scolyer, R., Yang, J., Mann, G., Wilkins, M. (2013). Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell & Melanoma Research, 26(5), 708-722. [More Information]
  • Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhie, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 45(4), 392-398. [More Information]
  • Kakavand, H., Scolyer, R., Thompson, J., Mann, G. (2013). Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. OncoImmunology, 2(9), e25564-1-e25564-3. [More Information]
  • Gyorki, D., Shaw, T., Nicholson, J., Baker, C., Pitcher, M., Skandarajah, A., Segelov, E., Mann, B. (2013). Improving the impact of didactic resident training with online spaced education. ANZ Journal of Surgery, 83(6), 477-480. [More Information]
  • Cust, A., Goumas, C., Vuong, K., Davies, J., Barrett, J., Holland, E., Schmid, H., Agha-Hamilton, C., Armstrong, B., Kefford, R., Mann, G., et al (2013). MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: An Australian case-control-family study. BMC Cancer, 13(1), 1-13. [More Information]
  • McLoone, J., Watts, K., Menzies, S., Barlow-Stewart, K., Mann, G., Kasparian, N. (2013). Melanoma survivors at high risk of developing new primary disease: a qualitative examination of the factors that contribute to patient satisfaction with clinical care. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(9), 1994-2000. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]
  • Schramm, S., Menzies, A., Mann, G. (2013). Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? Melanoma Research, 23(6), 423-425. [More Information]
  • Schramm, S., Jayaswal, V., Goel, A., Li, S., Yang, J., Mann, G., Wilkins, M. (2013). Molecular interaction networks for the analysis of human disease: utility, limitations, and considerations. Proteomics, 13(23-24), 3393-3405. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • McLoone, J., Menzies, S., Meiser, B., Mann, G., Kasparian, N. (2013). Psycho-educational interventions for melanoma survivors: a systematic review. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(7), 1444-1456. [More Information]
  • Jayaswal, V., Schramm, S., Mann, G., Wilkins, M., Yang, J. (2013). VAN: an R package for identifying biologically perturbed networks via differential variability analysis. BMC Research Notes, 6(1), 1-9. [More Information]

2012

  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Cust, A., Goumas, C., Holland, E., Agha-Hamilton, C., Aitken, J., Armstrong, B., Giles, G., Kefford, R., Schmid, H., Hopper, J., Mann, G., et al (2012). MC1R genotypes and risk of melanoma before age 40 years: A population-based case-control-family study. International Journal of Cancer, 131(3), E269-2E81. [More Information]
  • Coates, E., Moloney, F., Guitera, P., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Melanoma detection in high risk patients: a case series. 20th Regional Conference of Dermatology 2012.
  • Law, M., Montgomery, G., Brown, K., Martin, N., Mann, G., Hayward, N., MacGregor, S. (2012). Meta-Analysis Combining New and Existing Data Sets Confirms that the TERT-CLPTM1L Locus Influences Melanoma Risk. Journal of Investigative Dermatology, 132(2), 485-487. [More Information]
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., Mann, G., Menzies, S. (2012). Observation of a five year high risk clinic for primary melanoma. 3rd World Congress of Dermoscopy, Australia.
  • Schramm, S., Campain, A., Scolyer, R., Yang, J., Mann, G. (2012). Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. Journal of Investigative Dermatology, 132(2), 274-283. [More Information]
  • Scurr, L., McKenzie, H., Becker, T., Irvine, M., Lai, K., Mann, G., Scolyer, R., Kefford, R., Rizos, H. (2012). Selective Loss of Wild-Type p16(INK4a) Expression in Human Nevi. Journal of Investigative Dermatology, 131(11), 2329-2332. [More Information]
  • Howard, K., Salkeld, G., Mann, G., Patel, M., Cunich, M., Pignone, M. (2012). The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study. BMJ Open, 2(1), 1-6. [More Information]
  • Kasparian, N., Sansom-Daly, U., McDonald, R., Meiser, B., Butow, P., Mann, G. (2012). The nature and structure of psychological distress in people at high risk for melanoma: A factor analytic study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 21(8), 845-856. [More Information]

2011

  • Yokoyama, S., Woods, S., Boyle, G., Aoude, L., MacGregor, S., Zismann, V., Gartside, M., Cust, A., Haq, R., Harland, M., Holland, E., Schmid, H., Kefford, R., Armstrong, B., Mann, G., et al (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 480(7375), 99-103. [More Information]
  • Wakefield, C., Watts, K., Meiser, B., Sansom-Daly, U., Barratt, A., Mann, G., Lobb, E., Gaff, C., Howard, K., Patel, M. (2011). Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. Patient Education and Counseling, 83(1), 64-72. [More Information]
  • Cust, A., Jenkins, M., Goumas, C., Armstrong, B., Schmid, H., Aitken, J., Giles, G., Kefford, R., Hopper, J., Mann, G. (2011). Early-life sun exposure and risk of melanoma before age 40 years. Cancer Causes and Control, 22(6), 885-897. [More Information]
  • MacGregor, S., Montgomery, G., Liu, J., Zhao, Z., Henders, A., Stark, M., Schmid, H., Holland, E., Duffy, D., Zhang, M., Cust, A., Kefford, R., Armstrong, B., Mann, G., et al (2011). Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 43(11), 1114-1119. [More Information]
  • Amos, C., Wang, L., Lee, J., Gershenwald, J., Chen, W., Fang, S., Kosoy, R., Zhang, M., Qureshi, A., Vattathil, S., Mann, G., Cust, A., et al (2011). Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human Molecular Genetics, 20(24), 5012-5023. [More Information]
  • Barrett, J., Iles, M., Harland, M., Taylor, J., Aitken, J., Andresen, P., Akslen, L., Armstrong, B., Avril, M., Azizi, E., Cust, A., Kefford, R., Mann, G., et al (2011). Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 43(11), 1108-1113. [More Information]
  • Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]
  • Schramm, S., Mann, G. (2011). Melanoma Prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Molecular Cancer Therapeutics, 10(8), 1520-1528. [More Information]
  • Cust, A., Harland, M., Makalic, E., Schmidt, D., Dowty, J., Aitken, J., Agha-Hamilton, C., Armstrong, B., Barrett, J., Chan, M., Holland, E., Kefford, R., Schmid, H., Mann, G., et al (2011). Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. Journal of Medical Genetics, 48(4), 266-272. [More Information]
  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011). Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology, 29(10), 1239-1246. [More Information]
  • Cust, A., Armstrong, B., Goumas, C., Jenkins, M., Schmid, H., Hopper, J., Kefford, R., Giles, G., Aitken, J., Mann, G. (2011). Sunbed Use During Adolescence and Early Adulthood is Associated with Increased Risk of Early-Onset Melanoma. International Journal of Cancer, 128(10), 2425-2435. [More Information]

2010

  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]
  • Demenais, F., Mohamdi, H., Chaudru, V., Goldstein, A., Newton Bishop, J., Bishop, D., Kanetsky, P., Hayward, N., Gillanders, E., Elder, D., Holland, E., Mann, G., et al (2010). Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. Journal of the National Cancer Institute, 102(20), 1568-1583. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • McKenzie, H., Fung, C., Becker, T., Irvine, M., Mann, G., Kefford, R., Rizos, H. (2010). Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Human Mutation, 31(6), 692-701. [More Information]
  • Kasparian, N., Mcloone, J., Meiser, B., Butow, P., Simpson, J., Mann, G. (2010). Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. British Journal of Cancer, 103, 1502-1509. [More Information]

2009

  • Howard, K., Barratt, A., Mann, G., Patel, M. (2009). A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Archives of Internal Medicine, 169(17), 1603-1610. [More Information]
  • Morey, A., Murali, R., McCarthy, S., Mann, G., Scolyer, R. (2009). Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology, 41(4), 383-387. [More Information]
  • Scaini, M., Rossi, E., Torres, P., Zullato, D., Callegaro, M., Casella, C., Quaggio, M., Agata, S., Malacrida, S., Chiarion-Sileni, V., Mann, G., et al (2009). Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 671(1), 26-32. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Simpson, J., Mann, G. (2009). Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genetics in Medicine, 11(4), 265-278. [More Information]
  • Bishop, D., Demenais, F., Iles, M., Harland, M., Taylor, J., Corda, E., Randerson-Moor, J., Aitken, J., Kefford, R., Mann, G. (2009). Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 41(8), 920-925. [More Information]
  • Gartside, M., Chen, H., Ibrahimi, O., Byron, S., Curtis, A., Wellens, C., Bengston, A., Yudt, L., Eliseenkova, A., Ma, J., Mann, G., et al (2009). Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Molecular Cancer Research, 7(1), 41-54. [More Information]
  • Cust, A., Schmid, H., Maskiell, J., Jetann, J., Ferguson, M., Holland, E., Agha-Hamilton, C., Jenkins, M., Kelly, J., Kefford, R., Armstrong, B., Mann, G., et al (2009). Population-based, Case-Control-Family Design to Investigate Genetic and Environmental Influences on Melanoma Risk: Australian Melanoma Family Study. American Journal of Epidemiology, 170(12), 1541-1554. [More Information]
  • Leachman, S., Carucci, J., Kohlmann, W., Banks, K., Asgari, M., Bergman, W., Bianchi-Scarra, G., Brentnall, T., Bressac-de Paillerets, B., Bruno, W., Kefford, R., Mann, G. (2009). Selection criteria for genetic assessment of patients with familial melanoma. Journal Of The American Academy Of Dermatology, 61(4), 677.e1-677.e14. [More Information]
  • Becker, T., Haferkamp, S., Dijkstra, M., Scurr, L., Frausto, M., Diefenbach, E., Scolyer, R., Reisman, D., Mann, G., Kefford, R., Rizos, H. (2009). The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 8(4), 4-1-4-12. [More Information]

2008

  • Mann, G., Harland, M., Goldstein, A., Kukalizch, K., Taylor, C., Hogg, D., Puig, S., Badenase, C., Gruis, N., ter Huurnef, J., et al (2008). A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). European Journal of Cancer, 44(9), 1269-1274. [More Information]
  • Thompson, J., Armstrong, B., Barbour, A., Barnetson, R., Beanland, H., Beer, T., Brookshank, M., Burmeister, B., Butow, P., Clark, K., Conway, R., Damian, D., Frommer, M., Kefford, R., Lee, S., Mason, R., Mann, G., McCarthy, W., Menzies, S., Olver, I., Quinn, M., Saw, R., Shaw, H., Stretch, J., Barraclough, B., Holt, P., Reeve, T., et al (2008).
  • Brown, K., MacGregor, S., Montgomery, G., Craig, D., Zhao, Z., Iyadurai, K., Henders, A., Homer, N., Campbell, M., Stark, M., Schmid, H., Holland, E., Kefford, R., Armstrong, B., Mann, G., et al (2008). Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 40(7), 838-840. [More Information]
  • Kasparian, N., Butow, P., Meiser, B., Mann, G. (2008). High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 17(3), 270-279. [More Information]
  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]
  • Wakefield, C., Meiser, B., Gaff, C., Barratt, A., Patel, M., Suthers, G., Lobb, E., Ramsay, J., Mann, G. (2008). Issues Faced by Unaffected Men With a Family History of Prostate Cancer: A Multidisciplinary Overview. The Journal of Urology, 180(1), 38-46. [More Information]
  • Gallagher, S., Thompson, J., Indsto, J., Scurr, L., Lett, M., Gao, B., Dunleavey, R., Mann, G., Kefford, R., Rizos, H. (2008). p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. NeoPlasia: an international journal of oncology research, 10(11), 1231-1239. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Simpson, J., Mann, G. (2008). Predictors of psychological distress among individuals with a strong family history of malignant melanoma. Clinical Genetics, 73(2), 121-131. [More Information]

2007

  • Kasparian, N., Meiser, B., Butow, P., Job, R., Mann, G. (2007). Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 69-78.
  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Esquivel, J., Sticca, R., Sugarbaker, P., Levine, E., Yan, T., Alexander, R., Baratti, D., Bartlett, D., Barone, R., Barrios, P., et al (2007). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Annals of Surgical Oncology, 14(1), 128-133. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology & Therapeutics, 82(1), 33-40. [More Information]
  • Indsto, J., Kumar, S., Wang, L., Crotty, K., Arbuckle, S., Mann, G. (2007). Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. Journal Of Cutaneous Pathology, 34(6), 448-455. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]

2006

  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Soames Job, R., Mann, G. (2006). Anticipated uptake of genetic testing for familial melanoma in an Australian sample: an exploratory study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 69-78. [More Information]
  • Kasparian, N., Meiser, B., Butow, P., Job, R., Mann, G. (2006). Better the devil you know. High risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. Journal of Genetic Counseling, 15(6), 433-447. [More Information]
  • Goldstein, A., Chan, M., Harland, M., Hayward, N., Demenais, F., Bishop, D., Azizi, E., Bergman, W., Bianchi-Scarra, G., Bruno, W., Holland, E., Kefford, R., Mann, G., et al (2006). Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. Journal of Medical Genetics, 44(2), 99-106. [More Information]
  • Goldstein, A., Chan, M., Harland, M., Gillanders, E., Hayward, N., Avril, M., Azizi, E., Bianchi-Scarra, G., Bishop, D., Bressac-de Paillerets, B., Holland, E., Kefford, R., Mann, G., et al (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Research, 66(20), 9818-9828. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]

2005

  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology & Therapeutics, 77(1), 33-42. [More Information]
  • Becker, T., Rizos, H., Dela Pena, A., Leclercq, I., Woodruff, S., Kefford, R., Mann, G. (2005). Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochemical and Biophysical Research Communications, 332(3), 873-879. [More Information]
  • Harland, M., Taylor, C., Bass, S., Churchman, M., Randerson-Moor, J., Holland, E., Mann, G., Bishop, D., Newton Bishop, J. (2005). Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes and Cancer, 43(2), 128-136. [More Information]
  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]
  • Becker, T., Ayub, A., Kefford, R., Mann, G., Rizos, H. (2005). The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. International Journal of Cancer, 117(4), 569-573. [More Information]

2004

  • Walker, G., Indsto, J., Sood, R., Faruque, M., Hu, P., Pollock, P., Duray, P., Holland, E., Brown, K., Kefford, R., Mann, G., et al (2004). Deletion Mapping Suggests That The 1P22 Melanoma Susceptibility Gene Is A Tumor Suppressor Localized To A 9-Mb Interval. Genes Chromosomes and Cancer, 41(1), 56-64. [More Information]

2003

  • Clancy, J., Henderson, M., Russell, A., Anderson, D., Bova, R., Campbell, I., Choong, D., Macdonald, G., Mann, G., Nolan, T., Davies, M., et al (2003). EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene, 22(32), 5070-5081. [More Information]
  • Camp, E., Badhwar, P., Mann, G., Lardelli, M. (2003). Expression analysis of a tyrosinase promoter sequence in zebrafish. Pigment Cell Research, 16(2), 117-126.
  • Indsto, J., Nassif, N., Kefford, R., Mann, G. (2003). Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma. Clinical Cancer Research, 9(17), 6476-6482.
  • Kefford, R., Mann, G. (2003). Is there a role for genetic testing in patients with melanoma? Current Opinion in Oncology, 15(2), 157-161.
  • Gillanders, E., Juo, S., Holland, E., Jones, M., Nancarrow, D., Freas-Lutz, D., Sood, R., Park, N., Faruque, M., Markey, C., Kefford, R., Mann, G., et al (2003). Localization of a novel melanoma susceptibility locus to 1p22. American Journal of Human Genetics, 73(2), 301-313. [More Information]
  • Hornbuckle, J., Culjak, G., Jarvis, E., Gebski, V., Coates, A., Mann, G., Kefford, R. (2003). Patterns of metastases in familial and non-familial melanoma. Melanoma Research, 13(1), 105-109.

2002

  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.
  • Fung, D., Holland, E., Becker, T., Hayward, N., Bressac de Paillerets, B., Melanoma Genetics Consortium, M., Mann, G. (2002). EMelanoBase: An Online Locus-Specific Variant Database for Familial Melanoma. Human Mutation, 21(1), 2-7.
  • Thompson, D., Szabo, C., Mangion, J., Oldenburg, R., Odefrey, F., Seal, S., Barfoot, R., Kroeze-Jansema, K., Teare, D., Rahman, N., Mann, G., et al (2002). Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 99(2), 827-831.
  • Bishop, D., Demenais, F., Goldstein, A., Bergman, W., Bishop, J., Bressac de Paillerets, B., Chompret, A., Ghiorzo, P., Gruis, N., Hansson, J., Holland, E., Mann, G., et al (2002). Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma. Journal of the National Cancer Institute, 94(12), 894-903.

2001

  • Indsto, J., Cachia, A., Kefford, R., Mann, G. (2001). Clonality analysis, deletions and microsatellite instability in common acquired melanocytic nevi compared with malignant melanoma. Clinical Cancer Research, 7(12), 4054-4059.
  • Becker, T., Rizos, H., Kefford, R., Mann, G. (2001). Functional Impairment of Melanoma-associated p16 INK4a mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding1. Clinical Cancer Research, 7, 3282-3288.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R., Holland, E. (2001). Mutations in the INK4a/ARF Melanoma Susceptibility locus functionally impair p14ARF. Journal of Biological Chemistry, 276(44), 41424-41434.
  • Shannon, J., Kefford, R., Mann, G. (2001). Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds. Melanoma Research, 11(1), 1-9.
  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.
  • Indsto, J., Cachia, A., Kefford, R., Mann, G. (2001). X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi. Clinical Cancer Research, 7(12), 4054-4059.

2000

  • Cachia, A., Indsto, J., McLaren, K., Mann, G., Arends, M. (2000). CDKN2A mutation and deletion status in thin and thick primary melanoma. Clinical Cancer Research, 6(9), 3511-3515.
  • Harland, M., Holland, E., Ghiorzo, P., Mantelli, M., Bianchi-Scarra, G., Goldstein, A., Tucker, M., Ponder, B., Mann, G., Bishop, D., et al (2000). Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes and Cancer, 28(1), 45-57.
  • Rizos, H., Darmanian, A., Mann, G., Kefford, R. (2000). Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene, 19(26), 2978-2985.

To update your profile click here. For support on your academic profile contact .